{"id":"NCT00157950","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)","officialTitle":"An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2006-06","completion":"2006-06","firstPosted":"2005-09-12","resultsPosted":"2010-09-14","lastUpdate":"2016-02-04"},"enrollment":176,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Papillomavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Gardasil™","otherNames":["V501"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Gardasil™","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.","primaryOutcome":{"measure":"Number of Participants Who Seroconvert to HPV 6.","timeFrame":"Week 4 Postdose 3","effectByArm":[{"arm":"Gardasil™","deltaMin":109,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17986242","26930146"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":117},"commonTop":["Injection site pain","Injection site swelling","Injection site erythema","Fever","Cold"]}}